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Abstract
Presentation, management, and outcomes of COVID-19 infections among younger patients is an area of medicine with deficits
in research, likely due to the lower incidence of severe COVID-19 disease among the younger population. Management can
be challenging, and clinicians often guide their decision-making based on the ever-changing protocols that are tailored mostly
to the elderly population. Even more underrepresented in COVID-19 research are patients with chromosomal abnormalities
and trisomy syndromes, as they appear less frequently, but have risk of increased morbidity and mortality due to underlying
medical conditions. We describe a case of severe COVID-19 infection in a young patient with mosaic trisomy 13 and preexisting polycystic kidney disease, who developed severe acute hypoxic respiratory failure and acute chronic kidney injury.
The patient was provided maximal pharmacological support and her clinical course helps to shape the understanding of
COVID-19 infections in the setting of chromosomal abnormalities and complex medical history.
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Introduction
The coronavirus disease 2019 (COVID-19) pandemic caused
by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) continues to remain the focus of clinical and research
efforts by health care professionals globally. A large proportion of COVID-19-related deaths have involved the elderly,
with more than 70% of deaths in the United States involving
adults over the age of 70 years.1 However, the pediatric and
young adult population has not been completely immune to
SARS-CoV-2 infection, long-term sequelae, and mortality.
Children and young adults with COVID-19 generally experience a milder symptom profile compared to high-risk elderly
patients, with fever and cough being the most common presenting symptoms.2,3 However, even younger patients can
have severe and life-threatening COVID-19 in the presence
of pre-existing medical conditions.2,3 There are several congenital conditions and chromosomal abnormalities seen predominantly in pediatric and young adult populations.
Coupling the rarity of these congenital diseases with the significantly lower incidence of severe SARS-CoV-2 in younger
cohorts,4 it is not surprising that there is a paucity of literature documenting COVID-19 in these populations. As

COVID-19 moves toward endemic status globally, and new
variants continue to evolve, it becomes paramount to understand and document the variable presentation and clinical
course of COVID-19 in these rare populations.
Review of literature shows emerging evidence that children and adults with trisomy 21 (Down syndrome) are at
higher risk for severe COVID-19 with life-threatening complications.5,6 However, there are no published data on other
trisomy syndromes. Trisomy 13, also known as Patau syndrome, has a median life expectancy of 7–10 days, and 90%
of children die before the age of 1 year. However, the mosaic
form of trisomy 13 can have a variable clinical presentation,
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and be associated with relatively longer survival.7 We present a case of a young patient with complex medical history
of mosaic trisomy 13 and polycystic kidney disease (PKD),
who developed severe COVID-19 and subsequently died
secondary to complications.

Case presentation
A 20-year-old female with a complex medical history of
mosaic trisomy 13, PKD, asthma, seizure disorder, gastrictube dependence, and osteoporosis presented to our tertiary
medical center emergency department with respiratory distress, fever, vomiting, and diarrhea in setting of SARS-CoV-2
exposure through sibling. Her highest pre-hospitalization
temperature was 39.4°C, and her mother reported a home
pulse oximetry reading of 86% prompting presentation on the
fifth day of symptoms. The patient’s older brother who lived
in the same household had been feeling fatigued and febrile
for last 7 days, and tested positive for SARS-CoV-2 on the
same day as the patient’s presentation to our hospital. Since
the patient was restricted to home due to her chronic medical
condition, her mother was concerned that the patient may
have contracted COVID-19 from her brother. At baseline, this
young woman was non-verbal and wheelchair bound, and
seizures were controlled with oxcarbazepine (600 mg twice
daily) and levetiracetam (600 mg twice daily). Patient also
had chronic urinary incontinence at baseline requiring urinary
tract infection (UTI) prophylaxis with weekly alternating
nitrofurantoin (50 mg once daily) and trimethoprim/sulfamethoxazole (80/400 mg once daily).
Upon presentation, she was tachycardic (heart rate 107
beats/min) and hypoxic (oxygen saturation 86%), with respiratory rate of 24 breaths/minute, blood pressure of
143/84 mmHg, and temperature 36.4°C. She was acutely
distressed, with decreased breath sounds and crackles bilaterally. Her oxygen saturation improved with initiation of
high flow nasal canula and she received a dose of piperacillin–tazobactam (1 g piperacillin and 0.125 g tazobactam) for
empiric coverage due to concerns for potential aspiration.
The emergency medicine team presumably suspected aspiration based on her presentation with respiratory distress
and fever in setting of vomiting in addition to chronic disabilities that could potentially compromise airway protection. Initial labs reflected leukocytosis (white cell count
15.4 K/µL), abnormal urinalysis concerning for UTI, and
elevated inflammatory markers (ferritin 950 ng/mL,
C-reactive protein 33.90 mg/dL, procalcitonin 6.59 ng/mL).
In addition, she demonstrated metabolic derangements
including mild hyponatremia (130 mmol/L), hypochloremia
(95 mmol/L), and elevated blood urea nitrogen/creatinine
ratio (35.0). Chest x-ray (Figure 1) demonstrated diffuse
ground glass opacity appearance, suggestive of acute respiratory distress syndrome (ARDS). Her nasopharyngeal
SARS-CoV-2 PCR (polymerase chain reaction) test resulted
positive, and she was admitted to the intensive care unit for
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management of acute hypoxic respiratory failure secondary
to COVID-19. Piperacillin–tazobactam was not continued
during inpatient stay as positive SARS-CoV-2 test sufficiently explained her clinical presentation. During her
admission, electrolyte levels were monitored daily due to
her PKD (Figure 2 and Table 1).
Based on COVID-19 protocols at the time (August 2020),
she received remdesivir 100 mg from days 1 to 5, and convalescent plasma on day 2 of hospitalization. Dexamethasone
10 mg was also administered from days 1 to 5 and again from
days 8 to 12. For respiratory support, she was initiated on
high-flow nasal cannula at 40 L/min with FiO2 80%. This
was escalated to non-invasive mechanical ventilation with
bi-level positive airway pressure (BiPAP) on day 2 of admission due to worsening hypoxic respiratory failure (O2 saturations 87%), worsening chest x-ray findings, and persistent
tachycardia. Alternating prone positioning was also initiated
on day 2, but discontinued on day 5 of hospitalization due to
patient discomfort, and perceived lack of physiological
improvement.
Dexmedetomidine infusion was initiated to optimize
patient comfort and improve BiPAP synchrony. She received
enoxaparin 20 mg twice daily starting on day 1, and was
increased to 50 mg twice daily per COVID-19 protocols
when her d-dimer increased above 3000 ng/mL on day 4. On
admission urine culture, the patient grew Escherichia coli
sensitive to Cefepime and treatment was initiated (2 g every
12 h). Vancomycin was added on day 2 due to growth of
gram-positive cocci in her blood, but discontinued on day 3
when growth showed coagulase-negative cultures. On day 6
of hospitalization, patient’s hemoglobin was 6.4 gm/dL and
transfused two units of packed red blood cells.
Despite above treatments and supportive care, the
patient’s clinical status and labs continued to worsen (Table
1). By day 9, she had developed worsening acute kidney
injury (AKI), presumed secondary to kidney damage from
SARS-CoV-2 infection in setting of pre-existing PKD. In
setting of progressively worsening clinical status, on day
10, her parents elected to redirect care toward comfort
measures only. By day 12, she progressed to severe oliguria
unresponsive to diuretics or fluid resuscitation; parents
elected not to proceed with hemodialysis when offered the
option. Her respiratory status continued to worsen with
progressive hypercapnia (pCO2 86 mmHg) and worsening
lung infiltrates on chest x-ray (Figure 1) until her death on
day 13 of hospitalization.

Discussion
Trisomy 13 is found in 1 in 10,000 to 20,000 births and is the
third most common autosomal trisomy in live births.7 These
children may be born with microcephaly, midline facial
defects, and characteristic facial features such as small malformed ears, anophthalmia/microphthalmia, and micrognathia. Central nervous system abnormalities such as alobar
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Figure 1. Chest radiographs showing progression of COVID-19-related lung disease: chest x-ray on (a) presentation, (b) inpatient day
3, (c) day 6, and (d) inpatient day 11.

Figure 2. Long axis ultrasound images of (a) Right, and (b) Left sided polycystic kidneys.

holoprosencephaly, and congenital heart defects such as
atrio-ventricular septal defects and tetralogy of Fallot may be
present. In addition, lungs, liver, kidneys, and gastrointestinal tract may also be involved. Common limb abnormalities

such as polydactyly, talipes equinovarus, or rocker-bottom
feet are commonly present.8 While there is variability in life
expectancy, majority of affected infants die within the first
weeks of life. However, mosaicism occurs in 5% of trisomy
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E. coli: Escherichia coli; UTI: urinary tract infection; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; IV: intravenous.
a
N/A indicates not collected.

Maximum body temperature (°C)
d-dimer (ng/mL)
Fibrinogen (mg/dL)
Creatinine (mg/dL) (first
collection → second collection)
Treatments

Day 1 (admission)

Table 1. Notable laboratory markers and therapies during hospital course.
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13 cases, thus above-mentioned clinical features can vary
from mild to profound.9–11 This report describes SARSCoV-2 infection in a 20-year-old patient with severe clinical
features of mosaic trisomy 13, and the rarity of this condition
particularly at this age, makes this is a valuable addition to
the fund of COVID-19 literature.
Children and young adults have a much lower COVID19-related death rate than elderly counterparts,4 likely due to
their healthier status and fewer underlying medical conditions. Our patient, however, does not fall into this category,
as she had many co-morbid factors that may have resulted in
worsened disease process. While there is little information
on the interaction between COVID-19 and trisomy 13
patients, we can extrapolate from children with trisomy 21
who have increased mortality rates from COVID-19 infections (as do other children with intellectual/developmental
disabilities).5 Similar to trisomy 21, trisomy 13 can result in
abnormalities in upper airway anatomy and hypotonia, both
of which can result in worsening of respiratory infections.8
In addition, cardiopulmonary status of trisomy 13 patients is
an important consideration in that patients may be particularly vulnerable to pathology as a result of structural
malformations.8
Finally, dysregulation of an individual’s immune system
could play a role in developing severe infections; it has been
shown that patients with trisomy 21 can have variations in
immune functioning (lymphopenia, impaired chemotaxis,
etc.) that may contribute to the morbidity of respiratory
infections.6 While these data are specific to trisomy 21, it is
possible that similar challenges are contributing to disease
process in trisomy 13. Notably, our patient had persistently
low levels of total IgG diagnosed at age 5 years, which was
managed with monthly intravenous immunoglobulin (IVIG)
infusions when she was younger. The pediatric immunology
team had briefly trialed her off IVIG at age 10 years, but subsequently restarted due to persistently low levels. At the time
of presentation, our patient was receiving weekly subcutaneous immunoglobulin. Interestingly, the rapidly expanding
COVID-19 literature now includes several reports on successful use of IVIG as an adjuvant therapy, with favorable
outcomes in severe COVID-19 pneumonia.12 This should
perhaps also be considered as an adjuvant agent in COVID19 patients with chromosomal abnormalities and trisomy
syndromes, particularly in cases with documented immunoglobulin deficiency.
Respiratory support management was a particular challenge in the care of this patient, especially as her disease progressed. Because of persistently low oxygen saturation levels
and worsening respiratory distress, patient required support
via BiPAP, but only helped transiently. Trial of non-invasive
mechanical ventilation as initial support for COVID-19associated respiratory failure is standard therapy at this time.
However, it should be noted that our patient presented during
early stages of the pandemic, at a time when experts were
instead erring on the side of early intubation.13 In the case of
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our patient, intubation was considered; however, parental
guardians decided against full code measures including invasive mechanical ventilation via intubation. Our patient had a
history of chronic, well-controlled asthma; however, a
review of available literature does not point to a clear link
between asthma and trisomy 13. It can be argued that the
underlying asthma contributed to her disease severity, but we
would like to emphasize that she did not manifest any signs
of obstructive lung disease or status asthmaticus. Instead, her
pulmonary mechanics were consistent with poor compliance
secondary to parenchymal disease and ARDS.
Anticoagulation is an important consideration in the management of patients with COVID-19. It has been shown that
d-dimer levels have the most significant role in analyzing
coagulation status in patients with SARS-CoV-2 infections.14
Adjustments in our patient’s anticoagulation medications
were supported by studies finding lower 28-day mortality in
SARS-CoV-2-positive patients with d-dimer levels greater
than sixfold the upper limit of normal who received heparin
versus those who did not receive heparin.15
At the time of our patient’s hospitalization, there had been
two randomized clinical trials comparing 10-day treatment
of remdesivir, an antiviral agent, versus placebo; one of these
studies showed reduction of recovery time in patients receiving the antiviral.16 Similarly, a preliminary report at the time
supported the use of dexamethasone in hospitalized patients
receiving respiratory support, as it was shown to reduce
28-day mortality.17 This process is hypothesized to be related
to reduction of inflammatory-mediated lung injury, thus
improved respiratory status.17 Both agents have subsequently
showed benefit in severe COVID-19 pneumonia in setting of
end-stage renal disease, similar to our patient.18 Finally, the
use of convalescent plasma has been studied in the context of
previous viral outbreaks, including Ebola virus, Influenza A
H1N1, and Middle East respiratory syndrome coronavirus.19
Because of this information, convalescent plasma was identified relatively early in the COVID-19 pandemic as a possible treatment option in severe cases due to a potential
protective effect from antibodies of recovered patients.
Another major complication of this patient’s disease process was the rapid decline in kidney function. It is believed
that the SARS-CoV-2 infection directly resulted in AKI. As
found in other studies, AKI is a common result of this particular infection and is significantly more likely to occur in
COVID-19 positive patients.20 It is hypothesized that a variety of processes may contribute to renal decline, including
systemic collapse, pro-thrombotic states resulting in microemboli, and cytokine storms that can occur with SARSCoV-2. Our patient also had PKD, and although her renal
function was within normal limits prior to admission, it is
recognized that polycystic kidneys have underlying renal
dysfunction and an increased susceptibility to AKI induced
by ischemic-reperfusion injury.21 Therefore, it would be reasonable to assume that her PKD could have exacerbated the
COVID-19-associated AKI. Since 50%–60% of patients
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with trisomy 13 can have structural renal abnormalities, and
more than one-third of these are cystic kidney diseases,22
physicians caring for COVID-19 in trisomy 13 population
should be mindful of the theoretically higher risk of AKI.

Conclusion
Although vaccination efforts are spreading globally, new
variants of SARS-CoV-2 continue to emerge, and patient
populations with predisposing medical conditions will continue to be at high risk for severe disease and mortality.
Younger individuals with trisomy syndromes certainly
belong in this group, and we present one of the first reported
cases of SARS-CoV-2 in a patient with mosaic trisomy 13,
shedding light on the medical fragility of these patients and
their susceptibility to severe COVID-19.
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